For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240531:nRSe5235Qa&default-theme=true
RNS Number : 5235Q Futura Medical PLC 31 May 2024
Block Listing Six Monthly Return
31 May 2024
Futura Medical plc (AIM: FUM), the consumer healthcare company behind Eroxon,
that specialises in the development and global commercialisation of
innovative and clinically proven sexual health products, makes the following
update on its block listings, pursuant to AIM Rule 29 and Schedule Six of the
AIM Rules for Companies. All figures relate to options over Ordinary Shares of
0.2 pence each (Ordinary Shares).
Date: 31 May 2024
Name of applicant: Futura Medical Plc
Name of scheme(s): Unapproved Share Option Scheme
Unapproved Share Incentive Scheme
EMI Share Option Scheme
LTIP Scheme
Period of return: From: 1 December 2023 To: 31 May 2024
Balance of unallotted securities under scheme(s) from previous return: 20,782,665
Plus: The amount by which the block scheme(s) has been increased since the USOS: nil
date of the last return (if any increase has been applied for):
USIS: nil
EMI: nil
LTIP: nil
Less: Number of securities issued/allotted under scheme(s) during period: USOS: nil
USIS: nil
EMI: nil
LTIP: nil
Equals: Balance under scheme(s) not yet issued/allotted at end of period: 20,782,665
Number and class of securities originally admitted and the date of admission USOS Total: 3,882,912
814,424 25 May 2011
1,202,280 8 October 2013
1,466,208 25 May 2017
400,000 30 May 2018
USIS Total: 425,000
425,000 30 November 2018
EMI Total: 8,112,088
1,520,576 25 May 2011
1,467,720 8 October 2013
1,893,792 25 May 2017
790,000 30 May 2018
1,340,000 30 November 2018
1,100,000 2 February 2023
LTIP Total: 15,035,617
4,444,942 2 February 2023
10,590,675 3 November 2023
Contacts:
Futura Medical plc James Barder investor.relations@futuramedical.com
(mailto:Investor.relations@futuramedical.com)
Chief Executive Officer
+44 (0)1483 685 670
Angela Hildreth
www.futuramedical.com (http://www.futuramedical.com/)
Finance Director and COO
Liberum Phil Walker +44 (0)20 3100 2000
Nominated Adviser Richard Lindley
and Broker Nikhil Varghese
Stifel Nicolaus Europe Limited Alan Selby +44 (0)207 710 7600
Joint Broker Ben Maddison
Alma Strategic Communications Rebecca Sanders-Hewett +44 (0)20 3405 0205
Sam Modlin futura@almastrategic.com
Will Ellis Hancock
Notes to Editors:
Futura Medical plc (AIM: FUM) is the developer of innovative sexual health
products, including lead product Eroxon. Our core strength lies in our
research, development and commercialisation of topically delivered gel
formulations in sexual health products.
Eroxon, Futura's clinically proven lead product, has been developed for the
treatment of Erectile Dysfunction ("ED"). The highly differentiated product,
which is the only topical gel treatment for ED available over the counter and
helps men get an erection in ten minutes, addresses significant unmet needs
in the ED market.
ED impacts 1 in 5 men globally across all adult age brackets, with
approximately half of all men over 40 experiencing ED and 25% of all new
diagnoses being in men under 40.
Futura has distribution partners in place in a number of major consumer
markets including Haleon in the US, the largest market for ED in the world,
and Cooper Consumer Health in Europe. Eroxon has been nominated for a number
of healthcare industry awards and has won two to-date.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END BLRAMMATMTMJBFI